MAPT and Mental deterioration: Finally, we determined whether our suggested approach consisting of screening with plasma pTau217, followed by tau-PET only in those with elevated plasma pTau217, would be valuable when predicting cognitive decline in the BioFINDER-2 cohort (prognostic analyses not performed in TRIAD; see Methods).